Objective: Quality metrics were developed to improve outcomes after carotid artery revascularization; however, few studies have evaluated regional differences in perioperative outcomes. This study aimed to evaluate regional variation in mortality and perioperative outcomes after carotid endarterectomy (CEA) and carotid artery stenting (CAS).
Several studies focused on regional variation in surgical procedures and outcomes have shown that the providers' practices and the selection of patients play major roles in treatment decisions. [1] [2] [3] Recent data indicate that the same relationship may apply to carotid endarterectomy (CEA) and carotid artery stenting (CAS). The American Heart Association (AHA) and the Society for Vascular Surgery (SVS) developed a set of guidelines stating that carotid revascularization should be performed if the expected perioperative stroke/death risk is <6% in a symptomatic patient or 3% in an asymptomatic patient. [4] [5] [6] Despite these guidelines, limited data are published on the national trends of meeting and adhering to these standards. DeMartino et al 7 studied stroke rates after CEA using a national registry, the Vascular Quality Initiative (VQI), and noted that although most centers across the United States had a 30-day stroke rate below 2%, a subset of centers were higher. Selection of patients likely contributes to postoperative outcomes. We recently evaluated variation in the selection of patients and treatment of carotid artery disease across the United States and found that there was significant variation in the selection of patients and treatment, and many patients were treated outside of the guidelines set forth by the SVS. 8 We now aim to follow up on this initial analysis by evaluating the regional variation in perioperative outcomes in patients undergoing carotid artery revascularization.
METHODS
Database. We identified all patients who underwent CEA or CAS from 2009 to 2016 in the VQI. The VQI is a national clinical registry developed by the SVS to help improve patient care. It represents a collaboration between 18 regional quality groups, involving >420 hospitals and 3200 physicians. All regions are deidentified. Additional information about the registry can be found at www.vascularqualityinitiative.org/. The SVS VQI Research Advisory Committee and the Beth Israel Deaconess Medical Center Institutional Review Board approved this study and waived consent because of the deidentified nature of this data set.
Variables and outcomes. The primary outcome of this study was perioperative stroke/death. Secondary outcomes for both CEA and CAS included 30-day mortality, in-hospital stroke (stroke), myocardial infarction (MI), length of stay >2 days (prolonged length of stay), and use of intravenous blood pressure (IV BP) medication. We analyzed procedure-specific secondary outcomes as well. For CEA, this included cranial nerve injury (CNI), return to the operating room (OR), and discharge on aspirin as well as on antiplatelet and statin (antiplatelet/ statin). For CAS, we evaluated access site complication, discharge on dual antiplatelet therapy (DAPT), and discharge on statin. Outcomes were recorded after the index procedure and were defined by the VQI and thus cannot be modified. Symptomatic disease was defined as a history of ipsilateral ocular or cortical stroke or transient ischemic attack, with asymptomatic disease being all others to undergo intervention.
The definition of stroke included a composite of any ocular, cortical, or vertebral stroke symptoms persisting 24 hours or longer after the index procedure but before discharge. Postoperative MI was defined as elevated blood troponin levels (with or without clinical symptoms) or electrocardiographic changes consistent with MI. Prolonged length of stay was defined in accordance with the Physician Quality Reporting System measure 260, which states that asymptomatic patients should be discharged home by postoperative day 2 after CEA, as well as several studies that have investigated appropriate length of stay after carotid artery revascularization. [9] [10] [11] [12] [13] [14] CNI includes evidence of injury to cranial nerve VII, IX, X, or XII. Return to the OR includes any return in the index hospitalization. Access site complication was defined as a hematoma or pseudoaneurysm, either minimal or requiring transfusion or operation, or an arterial occlusion. For discharge medications (aspirin, antiplatelet, statin, and DAPT), the variable definition included patients prescribed medication at discharge, those not prescribed medication (either not medically indicated or those with a contraindication), and those who were noncompliant. For the purpose of our analysis, patients who did not tolerate medications or were noncompliant were excluded.
Statistical analysis. We conducted the statistical analysis using SPSS Statistics version 23 (IBM Corp, Armonk, NY) and produced all figures using GraphPad version 6.0 (GraphPad Software Inc, La Jolla, Calif). A c 2 analysis was used to compare variation across regions. Forest plots were used to represent the range of each variable across the 18 regions. Bar graphs were used to highlight specific outcomes, and the regions were lettered A to R to allow correlation of results of regions across different outcomes. We used letters instead of numbers to deidentify the regions further. We additionally paired the CEA and CAS data from each region to show that good outcomes in one procedure do not always correlate with good outcomes in the other. To calculate riskadjusted rates of 30-day stroke/death, we constructed hierarchical linear regression models allowing random Take Home Message: Analysis of data of 78,467 carotid endarterectomy patients revealed significant regional variations in outcome, many of which were outside of thresholds recommended by current guidelines. These outcome measures included periprocedural stroke and death, length of stay, and prescription of appropriate discharge medications.
ARTICLE HIGHLIGHTS
The authors recommend that regional Vascular Quality Initiative quality improvement projects for patients undergoing carotid procedures focus on areas that do not meet current practice guideline standards.
effects at the center level and used these to compute the marginal effects of region. Our linear regression model included previously published risk factors for mortality after carotid artery revascularization. 7, 15 We included age, symptom status, sex, race, surgery year, body mass index, prior aneurysm repair, chronic obstructive pulmonary disease, contralateral occlusion, chronic kidney disease (estimated glomerular filtration rate <60 mL/min/ 1.73 m 2 ), preoperative hemoglobin level <10 g/dL, coronary artery disease, smoking history, congestive heart failure, diabetes, antiplatelet therapy, and statin use. To minimize the effects of multiple comparisons, we performed a Holm-Bonferroni correction to set the statistical significance.
RESULTS
A total of 78,467 carotid artery revascularizations were performed, consisting of 66,169 CEA (69% asymptomatic) and 12,298 CAS (39% asymptomatic) procedures.
Asymptomatic patients. After CEA in asymptomatic patients, postoperative event rates varied in almost all outcomes (Fig 1) . Perioperative stroke/death rates were within the AHA guidelines for all regions (except for a single region with a rate of 3.1%) but did have significant regional variation in both the unadjusted and riskadjusted models (Fig 2) . Rates of 30-day mortality, however, did not differ significantly (0%-1.3%; P ¼ .2). Rates of postoperative MI ranged from 0.3% to 1.5% (P < .01) and CNI ranged from 0.9% to 4.9% (P < .01) across the regions.
Return to the OR also varied significantly from 0.9% to 3.4% (P < .01). Prolonged length of stay widely varied from 10% to 18% (P < .01). IV BP medication ranged from 16% to 35% (P < .01). Finally, discharge on aspirin and antiplatelet/ statin also varied widely (85%-95% [P < .01] and 75%-87% [P < .01], respectively; Figs 3 and 4).
Asymptomatic patients treated with CAS also experienced significant variation in their postoperative outcomes (Fig 5) . Rates of perioperative stroke/death did not vary significantly across regions in the unadjusted or risk-adjusted model. However, six regions had rates above AHA guidelines of 3%, five of which persisted after risk adjustment (Fig 2) . When the regions were sorted on the basis of the number of procedures performed, those with rates above the guidelines were evenly distributed above and below the median. Rates of 30-day mortality (0%-2.4%; P ¼ .2), stroke (0%-4.7%; P ¼ .2), and postoperative MI (0%-2.1%; P ¼ .3) did not differ significantly between the regions. Rates of access site complications ranged from 2.3% to 18.2% (P < .01). Prolonged length of stay varied from 5.3% to 25.7% (P < .01). IV BP medication did vary widely (11%-29%; P < .01), as did discharge not on DAPT (6%-21%; P < .01) and statin (77%-97%; P < .01; Figs 6 and 7).
Symptomatic patients. Rates of all postoperative outcomes varied across regions among symptomatic patients who underwent CEA (Fig 1) . Although all ranges were within the AHA guidelines of 6%, regional rates of stroke/ death varied significantly in both the unadjusted and risk-adjusted models (Fig 8) . Significant variation existed in rates of 30-day mortality (0%-1.8%; P < .01) as well as in postoperative MI (0%-3.3%; P < .01). Stroke rates varied across the regions but not significantly (1.3%-3.8%; P ¼ .05).
Rates of CNI ranged from 1.5% to 7.7% (P < .01); return to the OR, from 0.6% to 3.4% (P < .01); and prolonged length of stay, from 14% to 31% (P < .01). The use of IV BP medication (15%-40%; P < .01), discharge on aspirin (83%-96%; P < .01), and discharge on antiplatelet/statin (78%-91%; P < .01) varied significantly across the regions (Figs 3 and 4) . Finally, a number of postoperative outcomes varied after CAS in symptomatic patients (Fig 5) . Similar to asymptomatic patients, perioperative stroke/death did not vary significantly; however, two regions failed to meet the AHA guidelines in the unadjusted model, one of which remained after risk adjustment (2.4%-8.1%; P ¼ .1; Fig 8) . Although both regions were under the median for procedures performed, they were not in the lowest regions. Rates of 30-day mortality varied significantly from 0% to 4.6% (P ¼ .01), but not stroke (0.8%-5.0%; P ¼ .03) or MI (0.1%-2.3%; P ¼ .1). Variation existed in rates of access site complications (1.4%-16.9%; P < .01) and prolonged length of stay (11%-32%; P < .01). The use of IV BP medication varied widely (12%-29%; P < .01), as did discharge not on DAPT (7%-17%; P < .01) and discharge on statin (80%-93%; P < .01; Figs 6 and 7).
DISCUSSION
In this study, we reviewed perioperative outcomes in carotid artery revascularization across the United States and found significant variation throughout the 18 regions of the VQI. The more concerning finding is that outcomes from a number of the regions fall outside of the current standards.
Current AHA and SVS guidelines recommend performing carotid artery revascularization if the risk of stroke or death is <6% in symptomatic patients and 3% in asymptomatic patients. [4] [5] [6] These thresholds represent the point at which the benefits of revascularization outweigh the periprocedural risks, based on a number of ground-breaking trials. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] We found significant regional variation in rates of stroke and death after CEA; however, these rates all fell within the standards set by the AHA and SVS. Given that many regions were well below the 3% stroke/death rate in the asymptomatic CEA population as well as the evolutions in health care leading to lower perioperative risks, the thresholds that are presently set by the AHA and SVS may now be too high. This thought has been noted by others as well, and given this knowledge combined with the variation we found, these standards may warrant reconsideration. [26] [27] [28] [29] In contrast, stroke/death rates after CAS exceeded those set by the AHA and SVS guidelines in several regions. After risk adjustment in the asymptomatic population, five of six regions continued to exceed the rates set by the guidelines. Notably, symptomatic patients experienced rates exceeding 8%, almost 1.5 times greater than the national guideline threshold. Although this rate dropped after risk adjustment, it still remained above the 6% threshold. The results from our previously published work on variation in selection of patients and treatment also reinforce the idea that patients are not always selected appropriately. We found that in certain regions, as many as 4% of CEA patients and 15% of CAS patients were asymptomatic with stenosis <60%. 8 There are clear guidelines that recommend medical management in this subgroup of patients. 16, 17, 30 In addition, current guidelines are not clear on the use of CAS in the asymptomatic population, and trials, such as the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) and Asymptomatic Carotid Surgery Trial 2 (ACST-2), are under way to determine whether this subset of patients should undergo CAS. 6, 18, [31] [32] [33] A stroke/death rate of 6% for asymptomatic patients is unwarranted. Although the risk-adjusted rates after CAS dropped to within the guidelines for two regions, risk adjustment arguably should not be necessary in evaluating these outcomes. Clinicians performing CAS should be able to meet the pre-existing guidelines and should be cognizant of where they fall in relation to their peers. Each region has access to its data and should make corrections on the basis of the results. Unacceptable results in this cohort could be due to selection of patients, experience of the operator, technique, or low numbers (although at least 100 CAS procedures were performed in each region, and high-volume surgeons operated in highvolume regions). Current guidelines also recommend DAPT for at least 1 month after CAS. 6, [34] [35] [36] None of the regions in the VQI met 100% compliance with this guideline, with rates ranging from 79% to 94% in asymptomatic patients and 83% to 93% in symptomatic patients. Patients who did not tolerate the medication or were noncompliant were excluded from these figures, showing that the provider's preference is likely to be responsible for the ranges found. We acknowledge that 100% compliance is not a realistic expectation, but given the significant variation throughout the regions, prescribing practices should be a target for improvement. The Centers for Medicare and Medicaid Services and The Joint Commission have accomplished this in post-MI patients by developing a core measure set, which includes discharge medications. 37 potential targets for quality improvement projects. Many of these variables are modifiable, and clear updated guidelines could serve as the stimulus to improve outcomes.
The results of this study in combination with our initial analysis reveal profound variation in carotid artery revascularization throughout the regions of the VQI. Professional societies developed quality metrics and guidelines to standardize care and to improve postoperative outcomes. [4] [5] [6] These data reveal that despite efforts of clinicians to adhere to these guidelines, substantial room for improvement exists. Fortunately, initiatives such as the VQI provide regions and clinicians with feedback, allowing them to measure their outcomes against others across the United States to stimulate quality improvement projects. Outcomes such as stroke and death should vary little across regions, and all should fall under the thresholds set by the AHA and SVS. Moreover, as these guidelines are based on older data, they are rapidly becoming outdated. Recent trials, such as ACST-2 and CREST, demonstrate stroke/death rates in asymptomatic patients after CEA of close to 1%, calling into question the current threshold of 3%. 33, 34 As reporting of outcomes increases and is tied to physician reimbursement, the demand for meeting guidelines increases, as does the opportunity for quality improvement projects in areas where they fail. Moreover, because of the introduction of performance-based payment adjustments in Medicare, surgeons could lose up to 9% of their annual reimbursements by 2020 if they have above-average complication rates. 38 Although the regions in the VQI are deidentified, each has access to its own data. The onus falls on clinicians to ensure they are meeting these guidelines. This study must be interpreted in the context of its design. Although we ensure that each region had more than 100 CAS procedures, the data set is still relatively small, and therefore we may not be powered appropriately to detect rare outcomes. Second, although the VQI represents >420 hospitals, the data reflect only those institutions that choose to participate. In addition, the regions in the VQI are deidentified, and therefore we are unable to evaluate potential geographic influences, such as academic vs rural hospitals. Specialty is also deidentified, although the current AHA guidelines are in place for all clinicians who perform carotid revascularization. Prior work evaluating the management of other diseases with established AHA guidelines has shown similar regional variation, irrespective of specialty. 39 Last, this retrospective analysis uses prospectively collected data from multiple institutions, and with it exists the potential for missing data and coding errors. The VQI conducts an annual audit to minimize these issues. 
